

Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target

Jennifer Town^a, Helio Pais^a, Sally Harrison^{b,1}, Lucy F. Stead^{b,1}, Carole Bataille^c, Wilawan Bunjobpol^a, Jing Zhang^a, and Terence H. Rabbitts^{a,2}

^aMedical Research Council Molecular Haematology Unit, Weatherall Institute for Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, United Kingdom; ^bLeeds Institute of Molecular Medicine, St. James's Hospital, Leeds LS9 7TF, United Kingdom; and ^cChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3AT, United Kingdom

Edited by Owen N. Witte, Howard Hughes Medical Institute, University of California, Los Angeles, CA, and approved February 17, 2016 (received for review October 29, 2015)

The cell surface proteome of tumors mediates the interface between the transformed cells and the general microenvironment, including interactions with stromal cells in the tumor niche and immune cells such as T cells. In addition, the cell surface proteome of individual cancers defines biomarkers for that tumor type and potential proteins that can be the target of antibody-mediated therapy. We have used next-generation deep RNA sequencing (RNA-seq) coupled to an in-house database of genes encoding cell surface proteins (herein referred to as the surfaceome) as a tool to define a cell surface proteome of Ewing sarcoma compared with progenitor mesenchymal stem cells. This subtractive RNA-seq analysis revealed a specific surfaceome of Ewing and showed unexpectedly that the leucine-rich repeat and Ig domain protein 1 (LINGO1) is expressed in over 90% of Ewing sarcoma tumors, but not expressed in any other somatic tissue apart from the brain. We found that the LINGO1 protein acts as a gateway protein internalizing into the tumor cells when engaged by antibody and can carry antibody conjugated with drugs to kill Ewing sarcoma cells. Therefore, LINGO1 is a new, unique, and specific biomarker and drug target for the treatment of Ewing sarcoma.

Ewing sarcoma | LINGO1 | cell surface | antibody | cancer

Targeted cancer treatment options rely on the identification of specific target proteins that allow the differentiation between normal and malignant cells. Monoclonal antibodies that selectively bind to such target proteins have been successfully used in the clinic. Cell surface proteins are excellent targets for antibody-based therapeutics due to their accessibility. Mechanisms by which antibodies can induce tumor cell killing include antibody-dependent cell-mediated cytotoxicity (ADCC) and specific delivery of a cytotoxic payload to tumor cells using antibody-drug conjugates (ADCs) (1). However, there are few cancer-specific cell surface proteins that can be invoked for antibody targeting. Of the predicted number of ~21,000 human genes, ~4,700 are predicted to be membrane associated. Methods are required to filter this information and allow further prediction of cell surface molecules. The analysis of whole cellular transcriptomes by next-generation deep RNA sequencing (RNA-seq) is a new method for target discovery, which can be used as a surrogate tool for the analysis of the proteome, including the entirety of cell surface proteins, called the surfaceome (2, 3).

The Ewing sarcoma family of tumors (ESFT) is composed of aggressive bone and soft tissue tumors with a high propensity to metastasize. Ewing sarcoma is the second most common bone tumor of children and adolescents with the mean age of diagnosis being 15 y of age (4, 5). The current standard of care treatment is multimodal treatment, including systemic chemotherapy with either radiation or surgery often with limb amputation in patients with local recurrence (6, 7). However, despite aggressive treatment, the 5-y survival rate is 60–70% for localized disease and drops sharply to only 30% when the cancer metastasizes (4, 8). There is therefore a need for novel targeted therapies for these cancers, that will overcome the limitations of the current treatment regimens,

namely the severe side effects and very limited effectiveness for metastasized disease.

Ewing sarcoma (EWS) arises as a consequence of balanced chromosomal translocations, leading to an in-frame fusion of the EWS RNA-binding protein 1 (EWSR1) gene with a member of the ETS family of genes, principally resulting in fusion protein EWS–friend leukemia virus integration 1 (FLI1), which acts as an aberrant transcription factor and induces global changes in gene expression that are essential for malignant transformation and tumor formation (4). The most likely cells of origin of Ewing sarcoma are mesenchymal stem cells (MSCs) because these cells are permissive for EWS–FLI1, which is toxic for many cell lines (9, 10). In addition, EWS–FLI1 expression in MSCs induces a gene expression profile that is highly similar to EWS (11), whereas EWS–FLI1 silencing in ES cell lines leads to the conversion toward a MSC expression profile (12).

To facilitate the development of a general approach to identify candidate cell surface proteins, we examined the Ewing sarcoma cell surface using a new RNA-seq surfaceome database to analyze whole transcriptomes of polyA+ RNA from three cell lines with two MSC lines (subtractive RNA-seq). Our work on the Ewing sarcoma RNA-seq is a proof of concept and it revealed a set of candidate target proteins that are differentially expressed in the tumor cells. One of these target genes is the leucine-rich repeat and Ig domain-containing protein 1 (LINGO1) first identified as a component of protein complex on brain cells (13). Our data suggest that LINGO1 is a highly specific drug target and new biomarker of Ewing sarcoma tumors.

Results

Generation of a Database of Genes Encoding Surfaceome Proteins. The use of data for genes encoding cell surface proteins (the surfaceome) (3) has increasing importance because whole transcriptome

Significance

By investigating cell surface proteins of Ewing sarcoma we have identified an antigen that is uniquely expressed on these tumor cells compared with mesenchymal stem cells. This protein acts as a target for antibody drug conjugates that are internalized and can kill these tumor cells, presaging translating to clinical use in treating Ewing sarcoma, especially metastatic disease.

Author contributions: T.H.R. designed research; J.T., S.H., W.B., and J.Z. performed research; H.P., L.F.S., and C.B. contributed new reagents/analytic tools; J.T., H.P., L.F.S., and T.H.R. analyzed data; and J.T., H.P., S.H., L.F.S., J.Z., and T.H.R. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE73610).

¹Present address: Leeds Institute of Cancer & Pathology, St. James's Hospital, Leeds LS9 7TF, United Kingdom.

²To whom correspondence should be addressed. Email: terence.rabbitts@imm.ox.ac.uk.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1521251113/-DCSupplemental.




Fig. 1. Gene expression quantification by RNA-seq reveals differentially expressed genes in Ewing sarcoma. Mean expression values in the MSC lines are shown on the x axis and in the Ewing sarcoma cell lines on the y axis. Values are transcripts per million (TPM). Plots are shown for the entire transcriptome (A) or mRNA transcripts encoding surfaceome proteins (B). Each dot represents an mRNA transcript. Transcripts found to be significantly up-regulated in Ewing sarcoma or MSC are shown with red or blue dots, respectively. (For each transcript we carry out a modified *t* test using the three EWS values and the two MSC values. From this test we obtain a *P* value, corrected for multiple testing. A transcript is marked as up-regulated or down-regulated only if the corrected *P* value is smaller than 0.05). The numbers 1 through 10 in B indicate the surfaceome candidate target genes identified in Ewing sarcoma and 11 through 14, MSC-specific genes (SI Appendix, Dataset S2).

data can now be obtained by next-generation deep sequencing of populations of cells and single cells (14–16). Further, complete genome sequencing has defined all of the coding genes, allowing classification of gene products into functional categories and into subcellular locations, such as nucleus, mitochondria, membrane association, cell surface, and secreted. We have developed the surfaceome database based on the sources and criteria listed in [SI Appendix, Dataset S1A](#). The potential surfaceome genes were classified as gold, silver, or bronze ([SI Appendix, Dataset S1B](#)). These surfaceome database class designations were established to give degrees of confidence about the validity of each candidate surface protein encoding mRNA (for instance, gold is where a protein has been shown to have surface expression), whereas the two other classes distinguish higher and lower confidence in such predictions. Accordingly, next generation deep RNA-seq data can be filtered using the surfaceome database to list genes that will encode proteins at the cell surface and, by comparing two related cell populations, candidate

proteins can be identified that are differently expressed (subtractive RNA-seq).

Analysis of RNA-Seq Surfaceome Data Reveals Ewing Sarcoma Cell Surface Proteins. Possible novel surface proteins that could be therapeutic targets for Ewing sarcoma were investigated by implementing the filtering of whole transcriptome deep sequencing of RNA from three Ewing sarcoma cell lines (A673, TC-32, and TTC-466) compared with two MSC lines (5H and 4+v) (17). The complete datasets for the five RNA populations are given in [SI Appendix, Dataset S1](#). We compared the two whole transcriptomes with surfaceome-encoding transcripts (Fig. 1 and [SI Appendix, Fig. S2](#)) as well as transcription factors and cell cycle and cell signaling proteins ([SI Appendix, Figs. S1 and S2](#)). The subtracted surfaceome RNA-seq dataset is listed in [SI Appendix, Dataset S2](#). This dataset revealed 839 mRNA transcripts that are preferentially expressed in EWS and 931 transcripts that are preferentially expressed in the MSC lines (Fig. 1A). By filtering the RNA-seq data with our surfaceome database and subtracting between the two RNA-seq datasets, we found that 196 mRNAs are differentially expressed in Ewing sarcoma, with limited expression in MSCs, whereas 317 genes were up-regulated in the MSC lines (Fig. 1B). This total includes known Ewing sarcoma-associated proteins such as CD99 ([SI Appendix, Dataset S2](#)) but CD99 is known as a Ewing sarcoma marker and further CD99 mRNA expression did not fulfill the selectivity criteria used in our study.


The most highly differentially expressed candidate mRNAs in Ewing sarcoma were selected using more stringent criteria, i.e., high expression levels in all three EWS cell lines and no (or very low) expression in both MSC lines, excluding genes with high variability in their expression levels between the Ewing cell lines. This derived a set of 10 genes in Ewing sarcoma and 4 genes in the MSC that fit these criteria (*SI Appendix, Dataset S2*); these mRNAs are also indicated in Fig. 1*B*. The attribution of the expression of the 14 genes was confirmed by real-time PCR (qRT-PCR) using cDNA made from the three Ewing cell lines and the two MSC lines. All 10 candidate target genes expressed in the Ewing cell lines could not be detected in the MSC lines, whereas the four MSC-specific cells were detected in the MSC lines, but not in the Ewing cell lines (Fig. 2).

LINGO1 Is a Previously Unidentified Biomarker for Ewing Sarcoma Tumors. One of the mRNAs observed in the Ewing RNA-seq group encodes the leucine-repeat and Ig domain-containing protein LINGO1. The protein is expressed in neuronal tissue and is naturally part of the Nogo receptor (13, 18). A most striking characteristic of LINGO1 is its large and well-characterized extracellular domain (19). This characteristic made LINGO1 stand out as a potential new biomarker and drug target in Ewing sarcoma. The expression of *LINGO1* mRNA was studied in a larger panel of Ewing sarcoma cell lines, all of which carry the characteristic chromosomal translocations causing *EWS*-fusion genes. qRT-PCR analysis of eight Ewing sarcoma cell lines and three MSC lines shows that *LINGO1* mRNA could be detected in all of the EWS lines, whereas *LINGO1* was not detected in the MSC lines (Fig. 3A).

The analysis of the surfaceome by mRNA expression is a surrogate for the actual proteome and we therefore determined LINGO1 protein levels in the same panel of cell lines using Western blot analysis. Fig. 3B, *Upper* shows LINGO1 protein is detected in all of the Ewing cell lines, but not in the MSCs. We verified the presence of the EWS-FLI1 fusion protein by Western blotting with anti-FLI1 antibody (Fig. 3B, *Right*) or by Western blotting with anti-EWS in the three Ewing cell lines expressing the alternative fusion proteins EWS-ERG (TTC466 and RM82) or EWS-FEV (STAET10) (Fig. 3B, *Left*). In this analysis, the *Upper* band represents cellular EWS protein, whereas the *Bottom* band represents the fusion protein.

LINGO1 is expressed in all of the Ewing sarcoma cell lines tested. The spectrum of primary Ewing sarcoma patient expression was analyzed using tissue microarrays of paraffin-embedded

Fig. 3. LINGO1 is differentially expressed in Ewing sarcoma. The association of LINGO1 mRNA and protein in Ewing sarcoma cells was confirmed by qRT-PCR and immunoblotting. (A) qRT-PCR analysis of eight Ewing sarcoma cell lines and three MSC lines. *LINGO1* expression levels were normalized against the house-keeping gene *GAPDH* and the Ewing sarcoma cell line A673 was used as a reference. These are set at 1, i.e., $A673 = 100\%$. Relative expression levels are given as $RQ = 2^{-\Delta\Delta Ct}$ with $\Delta Ct = Ct_{LINGO1} - Ct_{GAPDH}$, $\Delta\Delta Ct = \Delta Ct_{Sample} - \Delta Ct_{A673}$. The error bars represent the 95% confidence interval of the RQ value. (B) Western blot analysis of LINGO1 protein. Lysates of Ewing sarcoma and MSC cells were fractionated by SDS/PAGE electrophoresis and analyzed by Western blotting using the anti-LINGO1 antibody (Abcam). Expression of EWS-FLI1 was shown in A673, TC-32, CHP100, SKNMC, and STAET1 (Right) using an anti-FLI1 antibody. Expression of either the alternative fusion protein EWS-ERG in TTC-466, RM82, or the EWS-FEV fusion in STAET100 (Left) was demonstrated using an anti-ERG antibody. Actin served as a protein loading control. (C) LINGO1 is expressed in primary Ewing sarcoma patient samples. Tissue microarrays containing cores from tumor biopsies were analyzed by immunohistochemistry using a mixture of two Alexa Fluor 488-coupled (green) anti-LINGO1 antibodies (Abcam and Millipore) and an Alexa-Fluor 594-coupled (red) anti-CD99 antibody (Thermo Scientific). Images were acquired by confocal laser scanning microscopy and analyzed using ImageJ software. LINGO1 expression levels were estimated based on staining intensities. Examples of weak (patient 1), medium (patient 2), and strong (patient 3) LINGO1-staining intensities are shown (summarized data are given in [SI Appendix, Table S3](#)). Paraffin-embedded MSC tissue culture cells served as a negative control. (Scale bars, 20 μm .)



majority of anti-LINGO1 antibody has been internalized and can be seen in the cytoplasm of the cells (Fig. 5A and B, Bottom). This has been visualized by time-lapse video shown in the [SI Appendix, Movie S1](#). A673 cells were incubated [37 °C in DMEM with 10% (vol/vol) FBS] with anti-LINGO1 Alexa Fluor 488 and green fluorescence time-lapse images overlaid with labeled acidic organelles (lysosomes) using LysoTracker Deep Red (red). Cells were incubated and images were collected at 25-s intervals for 1 h using the DeltaVision Elite Imaging System. After internalization, the anti-LINGO1 partially colocalized with the early endosomal and the lysosomal markers, suggesting that LINGO1 protein is internalized via the endosome-lysosome pathway, following binding with the anti-LINGO1 bivalent IgG antibody. As a negative control, MSCV4+v and HEK293 cells (nonexpressers of LINGO1 antigen) were incubated with or without anti-LINGO1 Alexa Fluor 488 ([SI Appendix, Movies S2–S4](#)).

LINGO1 Can Be Used as Target for Ewing Sarcoma Cell Killing. The unique cell surface expression of LINGO1 protein in Ewing sarcoma compared with other somatic tissues and the phenomenon of antibody-mediated internalization suggests that the protein can serve as a mediator of cell killing using ADCs. This situation was analyzed using doxorubicin in ADC assays with the A673 Ewing line because these cells are known to be doxorubicin sensitive (24). A dose-response analysis confirmed doxorubicin sensitivity at about 50 μM (Fig. 6A). The effect of anti-LINGO1 ADC was assayed in A673 (Fig. 6B) by coupling doxorubicin to anti-LINGO1 antibody Li81 and incubating either A673 cells or the MSC line 5Blast for up to 72 h. A673 cells were also incubated with Li81 antibody alone, without conjugated doxorubicin. Cell death was evident in the A673 cells incubated with the anti-LINGO1 ADC at 48 h, resulting in about 25% toxicity within the culture at 72 h (Fig. 6B). The ADC did not affect the percentage viability of the MSC cells, that lack LINGO1 expression, nor did the antibody alone affect the A673 viability.

Discussion

The Cancer Cell Surfaceome. The use of antibody therapies in human diseases, in particular cancer, is gaining importance, but a major technical challenge is finding the few cell surface proteins that provide distinguishing marks for specific cancer types. In addition,

with the advent of new technologies for tumor targeting, such as invoking T-cell responses with chimeric antigen receptors (25), the requirement for specific tumor cell surface markers has become a




Fig. 4. LINGO1 is expressed on the surface of Ewing sarcoma cell lines. LINGO1 surface expression (A, EWS) (B, MSC cell lines) was analyzed by FACS using the anti-LINGO1 antibody Li81 and a FITC-conjugated anti-human IgG secondary antibody. The x axis shows log₁₀ fluorescence intensities for LINGO1 antibody binding (blue), whereas the y axis shows cell counts normalized to maximum of cells collected for each cell line. The cell staining with second antibody-only is shown in red.




Fig. 5. LINGO1 protein internalizes on Ewing sarcoma cells and localizes to early endosomes and lysosomes after binding bivalent anti-LINGO1 antibody. A673 Ewing sarcoma cells were treated with Alexa 488-labeled (green) anti-LINGO1 Li81 antibody and incubated for 1.5 h at 4 °C or 37 °C. Cells were fixed and incubated with monoclonal rabbit antibody binding either the endosomal marker EEA1 (A) or the lysosomal marker LAMP1 (B) followed by incubation with Alexa 594-labeled (red) secondary anti-rabbit antibodies. Cell nuclei were stained using DAPI (blue).

critical component for implementing these methods. There are various possible approaches to determining the cell surface proteomes of a tumor types but an underexploited approach is to use the genome sequence and associated annotation resources that provides both the full gamut of human genes, their likely splice variants, and their protein products. By analyzing these sequence data, it is possible to classify gene products in terms of likely function but critically also subcellular location, in particular whether the proteins are likely to be at the cell surface.

We have used the human genome sequence data and motifs to sort the genes into those encoding proteins that are known to be, or have a likelihood to be, based on the presence of a membrane motif, cell surface proteins (the surfaceome database). This method builds on a previously published analysis (3) and now includes more comprehensive sets of proteins (all annotated gene products) and respective annotations (including both UniProt annotations and amino acid sequence feature predictions). We have assorted the proteins according to likelihood of cell surface expression as gold (known cell surface such as CD markers), silver (multiple independent feature predictions or annotations), and bronze (single feature prediction or annotation). This surfaceome database resource can be used to interrogate next generation deep RNA-seq data from a particular cell type to produce a cell-associated surfaceome. These data can be cell-type specific if suitable control RNA-seq data are available to allow subtraction of expression profiles (subtractive RNA-seq). This approach is applicable to human disease studies such as cancer biology and autoimmunity but also to developmental biology where cell surface changes influence cell fate (26).

LINGO1 Is a Potential Therapy Target in Ewing Sarcoma. We have applied this approach to assess surfaceome targets in Ewing sarcoma, which is an aggressive bone and soft-tissue sarcoma in adolescents and young adults. Current treatments involve

intensive chemotherapy, radiotherapy, and radical surgery. In an attempt to invoke molecular biology methods to identify new approaches to Ewing sarcoma therapy, we have generated RNA-seq data from tumor cells and compared these with data from mesenchymal stem cell lines to carry out subtractive RNA-seq. Among our list of differentially expressed candidate surfaceome targets were members of Ig-like domains, the G protein-coupled receptor superfamily, ion channels, as well as ion transporters (*SI Appendix, Dataset S2*) and includes seven proteins that have not previously been highlighted as EWS surface targets (LINGO1, KCNN1, CDH23, ADRA1D, SLC24A3, CACNA1H, and SLC29A4). A recent review has summarized available Ewing sarcoma transcriptome data (27). We have used our surfaceome database mining strategy to assess the published RNA-seq datasets (28, 29) (excluding one dataset that is currently not publicly available due to patient confidentiality) (30) and we found excellent concordance with the expression values found for our Ewing sarcoma surfaceome candidates shown in *SI Appendix, Dataset S2*. In both datasets, the expression level of




Fig. 6. Effect of doxorubicin anti-LINGO1 antibody drug conjugate on viability of Ewing sarcoma cells. (A) The Ewing sarcoma cell line A673 expressing LINGO1 surface antigen was tested for sensitivity to doxorubicin. Cells were incubated in the absence or presence of increasing concentrations of doxorubicin and the cell viability was counted using the PrestoBlue assay at 48 h. (B) Li81 anti-LINGO1 antibody was converted to an ADC using next generation maleimide (33) and in cell killing assays. A673 and MSC control cells were incubated for 48 or 72 h in the presence of 100 μg/mL Li81-ADC or Li81 alone. After the indicated incubation time, the cell viability was assayed using the PrestoBlue method. Values are normalized to cell number and viability of untreated cells.

the Ewing's up-regulated candidates positively correlates with the expression level of the translocation fusion *EWS-FLI1*, and conversely mRNAs up-regulated in MSC negatively correlates with *EWS-FLI1*. Among these outstanding proteins is LINGO1, which consists of 620 amino acids with a large extracellular domain, the structure of which has been elucidated by crystallography (19), and which is displayed at the cell surface, thereby favoring immune regulation approaches mediated by antibody binding.

LINGO1 is a prominent molecule because an extracellular Ig domain and a leucine repeat domain have provided antigenic epitopes for antibody derivation, including an anti-LINGO1 antibody that is currently in clinical trials (31). LINGO1 is a component of the Nogo receptor signaling complex and plays a role in regulation of neuronal survival, axon regeneration, oligodendrocyte differentiation, and myelination (13, 18). LINGO1 is exclusively expressed in the CNS (22) as we have verified with RT-PCR analysis of RNA from various mouse tissues (*SI Appendix*, Fig. S4). Brain-expressed LINGO1 is largely protected from circulating antibodies by the blood brain barrier. The restricted expression pattern and accessible extracellular domain make LINGO1 an attractive target for antibody-based therapies.

Our results show that an antibody binding to the extracellular domain of LINGO1 can induce cell killing when the anti-LINGO1 antibody carries a cytotoxic drug as an ADC. These immunological properties are presumably due to the efficient internalization of the cell surface LINGO1 protein on binding to the bivalent IgG1 antibody used. Thus, ADC is a most promising method for treatment of Ewing sarcoma. In Ewing, the site and size of the primary tumor are prognostic factors for outcome, but the most important factor is the presence of metastatic disease at presentation, which is an adverse factor. About a quarter of

patients present with disseminated disease and the front line therapy (surgery and chemotherapy) results in low 5-y survival. Recurrent disease is associated with a very poor prognosis and new therapeutic approaches are required (32). The use of targeting strategies to LINGO1 is a potentially novel approach to improve this outcome.

The expression of LINGO1 on brain cells is an issue with the use of antibodies carrying toxic drugs. The blood brain barrier is an effective gross prevention of blood supply because of the tight junctions of the vessel endothelium but some macromolecule movement is possible. Thus, ADC with anti-LINGO1 would need to be tested to assess this possible problem. Anti-LINGO1 bispecific antibodies could be an important approach to avoid toxicity issues. Special formulations of immunonanoparticles with drug payloads are developmental options that can also potentially overcome any toxicity issues.

Materials and Methods

For RNA-seq analysis of the MSC lines 5H and 4+v and the EWS cell lines, A673, TC-32, and TTC-466, total RNA was extracted and sequencing libraries were prepared before single end deep sequencing using an Illumina GA IIx to obtain 80-bp reads. RNA-seq data and surfaceome database analyses were carried out as described in *SI Appendix*. Other general methods and associated references are available online in *SI Appendix*.

Further supporting information and data files are available in *SI Appendix*.

ACKNOWLEDGMENTS. We thank Dr. Juan Funes and Prof. Chris Boshoff for the MSC cell lines; Prof. Bass Hassan and Dr. Harriet Brandford-White for the Ewing sarcoma cell lines CHP100, RM82, STAET1, and STAET10, the SKNMC cells, and the Ewing sarcoma tissue microarrays; and Prof. Andrew Bradbury for the IgG expression vectors. This work was supported by Grants from the Medical Research Council (MR/J000612/1), Wellcome Trust (099246/Z/12/Z), and Leukaemia and Lymphoma Research (12051).

- Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: Versatile platforms for cancer immunotherapy. *Nat Rev Immunol* 10(5):317–327.
- Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: A revolutionary tool for transcriptomics. *Nat Rev Genet* 10(1):57–63.
- da Cunha JP, et al. (2009) Bioinformatics construction of the human cell surfaceome. *Proc Natl Acad Sci USA* 106(39):16752–16757.
- Sankar S, Lessnick SL (2011) Promiscuous partnerships in Ewing's sarcoma. *Cancer Genet* 204(7):351–365.
- Terrier P, Lombart-Bosch A, Contesso G (1996) Small round blue cell tumors in bone: Prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. *Semin Diagn Pathol* 13(3):250–257.
- Abad R, Grimer R (2010) Surgical modalities in the treatment of bone sarcoma in children. *Cancer Treat Rev* 36(4):342–347.
- Potratz J, Dirksen U, Jürgens H, Craft A (2012) Ewing sarcoma: Clinical state-of-the-art. *Pediatr Hematol Oncol* 29(1):1–11.
- Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N; COG Bone Tumor Committee (2013) Children's Oncology Group's 2013 blueprint for research: Bone tumors. *Pediatr Blood Cancer* 60(6):1009–1015.
- Deneen B, Denny CT (2001) Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. *Oncogene* 20(46):6731–6741.
- Lessnick SL, Dacwag CS, Golub TR (2002) The Ewing's sarcoma oncoprotein EWS/FLI1 induces a p53-dependent growth arrest in primary human fibroblasts. *Cancer Cell* 1(4):393–401.
- Riggi N, et al. (2008) EWS-FLI1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. *Cancer Res* 68(7):2176–2185.
- Tirode F, et al. (2007) Mesenchymal stem cell features of Ewing tumors. *Cancer Cell* 11(5):421–429.
- Mi S, et al. (2004) LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. *Nat Neurosci* 7(3):221–228.
- Nagalakshmi U, et al. (2008) The transcriptional landscape of the yeast genome defined by RNA sequencing. *Science* 320(5881):1344–1349.
- Wilhelm BT, et al. (2008) Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. *Nature* 453(7199):1239–1243.
- Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods* 5(7):621–628.
- Wild L, Funes JM, Boshoff C, Flanagan JM (2010) In vitro transformation of mesenchymal stem cells induces gradual genomic hypomethylation. *Carcinogenesis* 31(10):1854–1862.
- Mi S, et al. (2005) LINGO-1 negatively regulates myelination by oligodendrocytes. *Nat Neurosci* 8(6):745–751.
- Mosyak L, et al. (2006) The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition. *J Biol Chem* 281(47):36378–36390.
- Staege MS, et al. (2004) DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. *Cancer Res* 64(22):8213–8221.
- Teicher BA, et al. (2015) Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. *Mol Cancer Ther* 14(11):2452–2462.
- Carim-Todd L, Escarceller M, Estivill X, Sumoy L (2003) LRRN6A/LERN1 (leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex. *Eur J Neurosci* 18(12):3167–3182.
- García-Aragoncillo E, et al. (2008) DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. *Oncogene* 27(46):6034–6043.
- Martins AS, et al. (2006) Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. *Clin Cancer Res* 12(11 Pt 1):3532–3540.
- Gill S, June CH (2015) Going viral: Chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunol Rev* 263(1):68–89.
- Rugg-Gunn PJ, et al. (2012) Cell-surface proteomics identifies lineage-specific markers of embryo-derived stem cells. *Dev Cell* 22(4):887–901.
- Sand LG, Szuhai K, Hogendoorn PC (2015) Sequencing overview of Ewing sarcoma: A journey across genomic, epigenomic and transcriptomic landscapes. *Int J Mol Sci* 16(7):16176–16215.
- Marques Howarth M, et al. (2014) Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. *J Clin Invest* 124(12):5275–5290.
- Riggi N, et al. (2014) EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. *Cancer Cell* 26(5):668–681.
- Brohl AS, et al. (2014) The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. *PLoS Genet* 10(7):e1004475.
- Tran JQ, et al. (2014) Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BLIB033. *Neuro Immunol Neuroinflamm* 1(2):e18.
- Gaspar N, et al. (2015) Ewing sarcoma: Current management and future approaches through collaboration. *J Clin Oncol* 33(27):3036–3046.
- Schumacher FF, et al. (2014) Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. *Org Biomol Chem* 12(37):7261–7269.